Umekar Milind, Chaudhary Anis Ahmad, Manghani Monali, Shidhaye Supriya, Khajone Pratiksha, Mahore Jayashri, Rudayni Hassan Ahmad, Trivedi Rashmi
Department of Pharmaceutics, Smt. Kishoritai Bhoyar College of Pharmacy, Kamptee, Nagpur 441002, Maharashtra, India.
Department of Biology, College of Science, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh 11623, Saudi Arabia.
Pharmaceutics. 2025 Jun 21;17(7):805. doi: 10.3390/pharmaceutics17070805.
Chronic wounds, including diabetic foot ulcers and pressure sores, are becoming more prevalent due to aging populations and increased metabolic problems. These wounds often persist due to impaired healing, chronic inflammation, oxidative stress, and infections caused by multidrug-resistant pathogens, making conventional treatments-including antibiotics and antiseptics-largely inadequate. This creates an urgent need for advanced, biologically responsive therapies that can both combat infection and promote tissue regeneration. Probiotics have surfaced as a viable option owing to their capacity to regulate immune responses, impede pathogenic biofilms, and generate antibacterial and antioxidant metabolites. However, their clinical application is limited by poor viability, sensitivity to environmental conditions, and short retention at wound sites. Nanotechnology-based delivery systems address these limitations by protecting probiotics from degradation, enhancing site-specific delivery, and enabling controlled, stimuli-responsive release. Encapsulation techniques using materials like chitosan, PLGA, liposomes, nanogels, nanofibers, and microneedles have shown significant success in improving wound healing outcomes in preclinical and clinical models. This review summarizes the current landscape of chronic wound challenges and presents recent advances in probiotic-loaded nanotechnologies. It explores various nano-delivery systems, their mechanisms of action, biological effects, and therapeutic outcomes, highlighting the synergy between probiotics and nanocarriers as a novel, multifaceted strategy for managing chronic wounds.
慢性伤口,包括糖尿病足溃疡和压疮,由于人口老龄化和代谢问题增多而日益普遍。由于愈合受损、慢性炎症、氧化应激以及多重耐药病原体引起的感染,这些伤口往往持续不愈,使得包括抗生素和防腐剂在内的传统治疗方法大多效果不佳。这就迫切需要先进的、具有生物响应性的疗法,既能对抗感染又能促进组织再生。益生菌因其调节免疫反应、阻碍致病生物膜形成以及产生抗菌和抗氧化代谢产物的能力而成为一种可行的选择。然而,它们的临床应用受到存活率低、对环境条件敏感以及在伤口部位停留时间短的限制。基于纳米技术的递送系统通过保护益生菌不被降解、增强靶向递送以及实现可控的、刺激响应释放来解决这些限制。使用壳聚糖、聚乳酸-羟基乙酸共聚物(PLGA)、脂质体、纳米凝胶、纳米纤维和微针等材料的封装技术在临床前和临床模型中已在改善伤口愈合结果方面取得了显著成功。本综述总结了慢性伤口面临的挑战现状,并介绍了载益生菌纳米技术的最新进展。它探讨了各种纳米递送系统、它们的作用机制、生物学效应和治疗效果,强调了益生菌与纳米载体之间的协同作用,这是一种管理慢性伤口的新型多方面策略。